Navigation Links
VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis
Date:7/28/2014

CARLISLE, Mass., July 28, 2014 /PRNewswire/ -- VigeneTech, Inc, in collaboration with BioLegend, Inc., today announced the release of LEGENDplex™ Data Analysis Software, an OEM software solution for analysis of multiplex data from flow cytometers.  BioLegend develops and offers varieties of bead-based multi-analyte immunoassay products for use with flow cytometers. With the support of VigeneTech's data analysis software, FCS data files can be  automatically and accurately analyzed and easily reported

LEGENDplex™ software is a robust data analysis package that automates flow cytometry data analysis and performs clustering analysis with the highest level of speed, accuracy, and reliability. Analysis results can be presented conveniently in 2D and 3D models and summary data exported and shared in multiple formats. Powered with VigeneTech's superior core technology of image segmentation and clustering analysis, LEGENDplex™ data analysis software excels in the market with its automated approach to clustered gating and unique algorithm in data analysis. The platform was designed in collaboration with BioLegend's comprehensive flow bead-based multi-analyte immunoassay products.  Together, they provide a complete solution for multiplex biomarker analysis in biological samples.

"LEGENDplex™ Data Analysis Software is our great extension in Flow Cytometry field. We are excited about this new addition in our product portfolio. With VigeneTech's image and data analysis engine and a new user interface, I foresee that it will really help researchers get FCS data analyzed with great ease." commented Mr. Shenzhi Yu, CIO of VigeneTech Inc..

BioLegend, Inc. develops world-class, cutting-edge antibodies, recombinant proteins and immunoassay products for biomedical research. Its product areas include cell immunophenotyping, cytokines and chemokines, adhesion, cancer research, T regulatory cells, stem cells, innate immunity, cell-cycle analysis, apoptosis, and modification-specific antibodies, etc.

[About VigeneTech]
VigeneTech is a leader in automated image and data analysis technology in protein and DNA/RNA fields. It provides novel software with customized solutions for various applications such as biomarker discovery, drug development, and diagnostic or other clinical and pre-clinical applications. VigeneTech's MicroVigene for DNA/RNA and protein microarray analysis delivers accurate and completely reproducible results. VigeneTech's CellVigene provides superior signal extraction for diagnostic and research applications in high content analysis, molecular image and other cell/tissue based images.  For more information, visit http://www.vigenetech.com


'/>"/>
SOURCE VigeneTech, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Essential Pharmaceuticals LLC releases Cell-Ess serum replacement for use in cell culture instead of FBS
2. VAPETEK Releases CBD-Infused eLiquid For The Consumer Market
3. New England Journal of Medicine releases study showing GSKs FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
4. Equashield Releases Markets Safest Closed System Drug Transfer Device for Medical Professionals
5. Health Care Logistics releases 2014 LumberJack Catalog today
6. Cephasonics Releases New cQuest Dragonfly Family of Ultra-Compact Ultrasound Systems
7. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
8. Nutrastar Releases Record Third Quarter 2013 Results
9. Certifications, Presentation of Study Results and Earnings Releases - Research Report on Agilent, Mindray, Bard, Tornier, and Life Technologies
10. Techne Corporation Releases Unaudited First Quarter Fiscal Year 2014 Results
11. Caradigm Releases Advanced Single Sign-On and Context Management Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... FRISCO, Texas , Dec. 8, 2016 /PRNewswire/ ... new program that brings leading-edge laboratory services and ... the United States , allowing more doctors ... and health care management solutions. Logo ... Hospital systems, under pressure to ...
(Date:12/8/2016)... , December 8, 2016 Information products ... metrics in Scopus , the world,s largest abstract ... access to comprehensive metrics for journals from over 5,000 publishers. The ... which journals to subscribe to and when to adjust a journal,s ... , , ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... ... (WCRI) officially opened registration today for its 33rd Annual Issues & Research ... . , The theme of the conference is “Persistent Challenges and New Opportunities: ...
(Date:12/8/2016)... ... 08, 2016 , ... CURE Media Group, the nation’s leading digital and print ... Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President ... “CURE Media Group is honored to team up with Upstage Lung Cancer in order ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... after surgery as possible. With this in mind, SIGVARIS has created a new ... blood clot) during bed rest and provide the benefits of graduated compression when ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... offices headquartered in Jefferson County, is announcing the launch of a charity drive ... The number of homeless women and children in Birmingham has grown steadily since ...
Breaking Medicine News(10 mins):